Regeneron’s $500M fund spotlights corporate venture’s influential role in biotech

When Regeneron announced a $500 million corporate venture capital fund last week, it was the first time in years that a storied large pharma had done so.

The company said it’s investing $100 million a year for five years.

Michael Aberman

“Our goal is to cultivate an ecosystem where the next generation of biotech companies can thrive, drawing on the lessons learned and successes achieved at Regeneron and throughout our careers,” Michael Aberman, one of the fund’s leaders, said in the press release at the time.

Regeneron’s move into corporate venture capital emphasizes how integral these funds are to nascent science and startups, and it’s another reminder that a check from a corporate VC increases the likelihood of a biotech’s M&A exit. Many of the largest pharma companies operate their own funds, though few new ones have launched in recent years,…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks